Buruli Ulcer : : Mycobacterium Ulcerans Disease.
Saved in:
: | |
---|---|
TeilnehmendeR: | |
Place / Publishing House: | Cham : : Springer International Publishing AG,, 2019. ©2019. |
Year of Publication: | 2019 |
Edition: | 1st ed. |
Language: | English |
Online Access: | |
Physical Description: | 1 online resource (290 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
5005771208 |
---|---|
ctrlnum |
(MiAaPQ)5005771208 (Au-PeEL)EBL5771208 (OCoLC)1099692389 |
collection |
bib_alma |
record_format |
marc |
spelling |
Pluschke, Gerd. Buruli Ulcer : Mycobacterium Ulcerans Disease. 1st ed. Cham : Springer International Publishing AG, 2019. ©2019. 1 online resource (290 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Intro -- Preface -- Contents -- Buruli Ulcer: History and Disease Burden -- Buruli Ulcer in Africa -- 1 Introduction -- 2 Management of BU in Africa -- 2.1 Structure of Health Systems in Africa and Implications for the Management of BU -- 2.2 Diagnosis and Treatment of BU -- 3 Geographical Distribution of BU: Reporting of Cases Versus Actual Situation in Africa -- 4 Distribution of BU Among Affected Populations in Africa -- 5 The Etiology of BU in Africa -- 6 Future Perspectives -- References -- Buruli Ulcer in Australia -- 1 Bairnsdale Ulcer and the Discovery of Mycobacterium ulcerans -- 2 Buruli Ulcer in Queensland -- 3 Buruli Ulcer in Victoria -- 4 Buruli Ulcer in Animals in Victoria -- 5 Recent Epidemiology of Buruli Ulcer in Victoria -- 6 Clinical Management of Buruli Ulcer in Australia -- 7 Buruli Ulcer: The Australian Paradox -- References -- Mycobacterium ulcerans Infection in French Guiana -- Current State of Knowledge -- 1 Introduction -- 2 Links Between the Human Host and the Bacteria -- 2.1 Risk Factors of BU in French Guiana -- 2.2 Epidemiology and Clinical Aspects of BU in French Guiana -- 2.3 A Link Between Rainfall and BU Cases -- 2.4 Genetic Diversity of M. ulcerans Among Local BU Cases -- 3 Environment and the Bacteria -- 3.1 First Detection of Mycobacterium ulcerans DNA in Environmental Samples from French Guiana -- 3.2 Biodiversity Drivers of M. ulcerans Distribution Across Freshwater Habitats -- 4 Conclusion -- References -- Buruli Ulcer in Japan -- 1 Epidemiology and Bacteriological and Genomic Features of M. ulcerans subsp. shinshuense -- 1.1 Epidemiology -- 1.2 Genome -- 1.3 Biochemical Properties -- 2 Clinical Features and Treatment of BU in Japan -- 2.1 Antimicrobial Treatment -- 2.2 Alternative Treatments of BU -- 2.3 Other Suggested Therapies. 3 M. ulcerans subsp. shinshuense in the Environment of Japan -- 3.1 Detection of Environmental M. ulcerans subsp. shinshuense in Japan -- 3.2 Seasonal Variation of BU in Japan -- 3.3 PCR Detection of M. ulcerans subsp. shinshuense DNA in the Environment -- 4 BU in Asia and Future Perspectives -- 4.1 BU in China -- 4.2 Toward Detection of BU in Other Asian Countries -- References -- Population Genomics and Molecular Epidemiology of Mycobacterium ulcerans -- 1 First Insights from the Complete Genome of Mycobacterium ulcerans -- 2 An Aquatic Origin and Two Bottlenecks for a Recently Emerged, and Globally Distributed Pathogen -- 3 New Understandings from Genomics on the Spread of M. ulcerans Across Africa -- 4 Genomic Approaches to Micro-Molecular Epidemiological Investigations of BU -- 5 Distinguishing Relapse from Reinfection and Familial Studies -- 6 Summary and Future Perspectives -- References -- Mycolactone: More than Just a Cytotoxin -- 1 Mycolactone and BU Disease -- 1.1 Pharmacodistribution -- 1.2 Mycolactone Contribution to BU Disease Manifestations -- 1.2.1 Pathogenesis and Histopathology of BU Lesions -- 1.2.2 Local Analgesia -- 1.2.3 Local and Systemic Immunomodulation -- 2 Molecular Targets and Mechanisms of Action -- 2.1 Sec61 Blockade -- 2.2 AT2R Stimulation -- 2.3 N-WASP Activation -- 3 Conclusions -- References -- The Immunology of Buruli Ulcer -- 1 Buruli Ulcer: The First Histological Observations of a Necrotic Track -- 2 Host Attempts to Control Mycobacterium ulcerans Infection -- 2.1 Local Immune Response -- 2.2 Regional and Systemic Responses -- 3 Diagnostics Research Make it Evident: The Triggering of Cellular and Humoral Arms -- 4 Antibiotic Treatment in the Aid of the Host Immune Response -- 5 Epidemiological Clues and the Search for Novel Resistance and Susceptibility Markers. 6 (Un)successful Preventive Approaches -- 7 Novel Models for Investigation and Future Perspectives -- 8 Conclusions -- References -- Buruli Ulcer in Animals and Experimental Infection Models -- 1 Naturally Infected Animals -- 2 The Mouse (Mus musculus) Model -- 2.1 History of the BU Mouse Model -- 2.2 Experimental Infection of the Mouse -- 2.2.1 Infection Sites -- 2.2.2 Mouse Strains -- 2.2.3 Mycobacterial Strains Used for Experimental Infection -- 2.2.4 Dose and Preparation of the Bacterial Inocula -- 2.2.5 Infection Outcomes and What to Measure -- 2.3 Research Applications for the Mouse Model -- 2.3.1 Antimicrobial Compound Testing -- 2.3.2 Vaccine Development -- 2.3.3 Study of the Pathogenesis of Buruli Ulcer and the Immune Response to the Disease -- 3 Other Animal Models -- 3.1 Guinea Pig (Cavia porcellus) -- 3.2 Pig (Sus scrofa) -- 3.3 Grasscutter (Thryonomys swinderianus) -- 3.4 Anole Lizard (Anolis carolinensis) -- 3.5 Nine-Banded Armadillo (Dasypus novemcinctus) -- 3.6 Cynomologus Monkey (Maca fascicularis) -- 3.7 African Rat (Mastomys natalensis) -- 3.8 Common Brushtail Possum (Trichosurus vulpecula) -- 4 Conclusions -- References -- Laboratory Diagnosis of Buruli Ulcer: Challenges and Future Perspectives -- 1 Introduction -- 2 Currently Available Laboratory Diagnostic Tests -- 2.1 Specimen Collection and Reference Standards -- 2.2 IS2404 PCR: The Current Gold Standard -- 2.3 Detection of AFBs by Microscopy: A Test for the Primary Healthcare Level with Limited Sensitivity -- 2.4 Considerations on the Accuracy of IS2404 qPCR and AFB Detection by Microscopy: Direct Comparison of the Two Techniques -- 2.5 Histopathology and Cultivation of M. ulcerans: Research Tools Rather than Diagnostic Tests -- 2.6 From Theory into Practice: Diagnosis of BU in Resource-Constrained Endemic Countries. 3 Development of BU Diagnostics for District Hospital or Primary Healthcare Facility Level -- 3.1 LAMP: An Alternative for the Detection of M. ulcerans DNA -- 3.2 Detection of Mycolactone by f-TLC: Struggling with the Complexity of Lipid Extracts -- 3.3 Serological Tests: Only Suitable for Seroepidemiological Studies -- 3.4 Detection of Mycolactone and M. ulcerans Proteins by Antigen Detection Assays: Prospects for the Development of an RDT -- 4 Discussion -- 5 Outlook -- References -- Antimicrobial Treatment of Mycobacterium ulcerans Infection -- 1 Historical Aspects -- 2 Antimicrobial Susceptibility of M. ulcerans -- 2.1 Ansamycins/Rifamycins -- 2.2 Aminoglycosides: Streptomycin -- 2.3 Amikacin -- 2.4 Macrolides: Clarithromycin -- 2.5 Azithromycin -- 2.6 Fluoroquinolones -- 2.7 Clofazimine -- 2.8 Dapsone -- 2.9 Doxycycline -- 2.10 Oxazolidinones -- 2.11 Avermectins -- 2.12 Trimethoprim and Epiroprim -- 3 Experimental Drugs -- 4 Clinical Studies -- 4.1 Secondary Infection -- 4.2 HIV Co-infection -- 5 Conclusions -- Areas of Uncertainty -- and Future Directions -- References -- Thermotherapy of Buruli Ulcer -- References -- Secondary Infection of Buruli Ulcer Lesions -- 1 Background -- 2 Bacterial Species Associated with Secondary Infections -- 2.1 Species Diversity -- 3 Bacterial Burden -- 4 Diagnosing Secondary Infection in BU -- 5 Drug Susceptibility Patterns of Bacterial Isolates from BU Lesions -- 6 Molecular Epidemiology -- 6.1 Sources of Infection -- 7 Predisposing Socio-Economic Factors -- 8 Prevention of Secondary Infection -- 9 Wound Care -- References -- Management of BU-HIV Co-infection -- 1 Epidemiology -- 2 Clinical Effects of BU-HIV Co-Infection -- 3 Diagnosis -- 4 Management of BU-HIV Co-Infection -- 4.1 BU Treatment -- 4.2 HIV Treatment -- 4.3 HIV and BU Treatment Interactions. 4.4 Children -- 4.5 Tuberculosis -- 4.6 Service Provision -- References -- Social Science Contributions to BU Focused Health Service Research in West-Africa -- 1 Introduction -- 2 Part One -- 2.1 Predisposing Factors: Cultural Perceptions of BU Causality, Social Stigma, and Preference for Traditional Healing -- 2.1.1 Cultural Perceptions of BU Causality -- Benin -- Cameroon -- Ghana -- 2.1.2 Stigma and Social Risk -- 2.1.3 Traditional Healers -- Enabling Factors -- 2.2 Service Level Factors Affecting Health Care Seeking and Treatment Adherence -- 3 Part Two: Social Science Inspired Interventions -- 3.1 Outreach Education -- 3.2 Introducing Decentralized BU Care in Ouinhi, Benin -- 3.3 Establishing a BU Community of Practice: Cameroon -- 3.4 Yaws Cases Identified as a Result of BU Outreach in Cameroon: A Case for Integrated Skin Neglected Tropical Disease (NTD) Programs -- 3.5 BU Children's Support Group Ghana -- 3.6 Mhealth as a Tool in Monitoring BU Healing in Ghana -- 3.7 Transforming a BU Hospital into a Therapeutic Community for Inpatients -- 4 Conclusion -- References -- Transdisciplinary Research and Action to Stop Buruli Ulcer: A case Study from Philanthropy -- 1 Introduction -- 2 The Beginnings: Six Reasons Why -- 2.1 Reason #1: Lack of Funding Incentives -- 2.2 Reason #2: A Disease of Social Justice -- 2.3 Reason #3: A Disease with Devastating Consequences -- 2.4 Reason #4: The Pioneer Effect -- 2.5 Reason #5: Existing Critical Mass of Researchers and Implementing Agencies -- 2.6 Reason #6: Scalability and Uptake -- 2.7 Stop Buruli Initiative -- 3 The Model: Transdisciplinary Research and Implementation -- 4 Key Elements for Advancing Transdisciplinarity -- 4.1 Transdisciplinarity Does Not 'Just Happen' -- 4.2 Governance Model -- 5 Results -- 5.1 Diagnosis -- 5.2 Treatment -- 5.3 Transmission. 5.4 Socio-Cultural Aspects. Description based on publisher supplied metadata and other sources. Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. Electronic books. Röltgen, Katharina. Print version: Pluschke, Gerd Buruli Ulcer Cham : Springer International Publishing AG,c2019 9783030111137 ProQuest (Firm) https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=5771208 Click to View |
language |
English |
format |
eBook |
author |
Pluschke, Gerd. |
spellingShingle |
Pluschke, Gerd. Buruli Ulcer : Mycobacterium Ulcerans Disease. Intro -- Preface -- Contents -- Buruli Ulcer: History and Disease Burden -- Buruli Ulcer in Africa -- 1 Introduction -- 2 Management of BU in Africa -- 2.1 Structure of Health Systems in Africa and Implications for the Management of BU -- 2.2 Diagnosis and Treatment of BU -- 3 Geographical Distribution of BU: Reporting of Cases Versus Actual Situation in Africa -- 4 Distribution of BU Among Affected Populations in Africa -- 5 The Etiology of BU in Africa -- 6 Future Perspectives -- References -- Buruli Ulcer in Australia -- 1 Bairnsdale Ulcer and the Discovery of Mycobacterium ulcerans -- 2 Buruli Ulcer in Queensland -- 3 Buruli Ulcer in Victoria -- 4 Buruli Ulcer in Animals in Victoria -- 5 Recent Epidemiology of Buruli Ulcer in Victoria -- 6 Clinical Management of Buruli Ulcer in Australia -- 7 Buruli Ulcer: The Australian Paradox -- References -- Mycobacterium ulcerans Infection in French Guiana -- Current State of Knowledge -- 1 Introduction -- 2 Links Between the Human Host and the Bacteria -- 2.1 Risk Factors of BU in French Guiana -- 2.2 Epidemiology and Clinical Aspects of BU in French Guiana -- 2.3 A Link Between Rainfall and BU Cases -- 2.4 Genetic Diversity of M. ulcerans Among Local BU Cases -- 3 Environment and the Bacteria -- 3.1 First Detection of Mycobacterium ulcerans DNA in Environmental Samples from French Guiana -- 3.2 Biodiversity Drivers of M. ulcerans Distribution Across Freshwater Habitats -- 4 Conclusion -- References -- Buruli Ulcer in Japan -- 1 Epidemiology and Bacteriological and Genomic Features of M. ulcerans subsp. shinshuense -- 1.1 Epidemiology -- 1.2 Genome -- 1.3 Biochemical Properties -- 2 Clinical Features and Treatment of BU in Japan -- 2.1 Antimicrobial Treatment -- 2.2 Alternative Treatments of BU -- 2.3 Other Suggested Therapies. 3 M. ulcerans subsp. shinshuense in the Environment of Japan -- 3.1 Detection of Environmental M. ulcerans subsp. shinshuense in Japan -- 3.2 Seasonal Variation of BU in Japan -- 3.3 PCR Detection of M. ulcerans subsp. shinshuense DNA in the Environment -- 4 BU in Asia and Future Perspectives -- 4.1 BU in China -- 4.2 Toward Detection of BU in Other Asian Countries -- References -- Population Genomics and Molecular Epidemiology of Mycobacterium ulcerans -- 1 First Insights from the Complete Genome of Mycobacterium ulcerans -- 2 An Aquatic Origin and Two Bottlenecks for a Recently Emerged, and Globally Distributed Pathogen -- 3 New Understandings from Genomics on the Spread of M. ulcerans Across Africa -- 4 Genomic Approaches to Micro-Molecular Epidemiological Investigations of BU -- 5 Distinguishing Relapse from Reinfection and Familial Studies -- 6 Summary and Future Perspectives -- References -- Mycolactone: More than Just a Cytotoxin -- 1 Mycolactone and BU Disease -- 1.1 Pharmacodistribution -- 1.2 Mycolactone Contribution to BU Disease Manifestations -- 1.2.1 Pathogenesis and Histopathology of BU Lesions -- 1.2.2 Local Analgesia -- 1.2.3 Local and Systemic Immunomodulation -- 2 Molecular Targets and Mechanisms of Action -- 2.1 Sec61 Blockade -- 2.2 AT2R Stimulation -- 2.3 N-WASP Activation -- 3 Conclusions -- References -- The Immunology of Buruli Ulcer -- 1 Buruli Ulcer: The First Histological Observations of a Necrotic Track -- 2 Host Attempts to Control Mycobacterium ulcerans Infection -- 2.1 Local Immune Response -- 2.2 Regional and Systemic Responses -- 3 Diagnostics Research Make it Evident: The Triggering of Cellular and Humoral Arms -- 4 Antibiotic Treatment in the Aid of the Host Immune Response -- 5 Epidemiological Clues and the Search for Novel Resistance and Susceptibility Markers. 6 (Un)successful Preventive Approaches -- 7 Novel Models for Investigation and Future Perspectives -- 8 Conclusions -- References -- Buruli Ulcer in Animals and Experimental Infection Models -- 1 Naturally Infected Animals -- 2 The Mouse (Mus musculus) Model -- 2.1 History of the BU Mouse Model -- 2.2 Experimental Infection of the Mouse -- 2.2.1 Infection Sites -- 2.2.2 Mouse Strains -- 2.2.3 Mycobacterial Strains Used for Experimental Infection -- 2.2.4 Dose and Preparation of the Bacterial Inocula -- 2.2.5 Infection Outcomes and What to Measure -- 2.3 Research Applications for the Mouse Model -- 2.3.1 Antimicrobial Compound Testing -- 2.3.2 Vaccine Development -- 2.3.3 Study of the Pathogenesis of Buruli Ulcer and the Immune Response to the Disease -- 3 Other Animal Models -- 3.1 Guinea Pig (Cavia porcellus) -- 3.2 Pig (Sus scrofa) -- 3.3 Grasscutter (Thryonomys swinderianus) -- 3.4 Anole Lizard (Anolis carolinensis) -- 3.5 Nine-Banded Armadillo (Dasypus novemcinctus) -- 3.6 Cynomologus Monkey (Maca fascicularis) -- 3.7 African Rat (Mastomys natalensis) -- 3.8 Common Brushtail Possum (Trichosurus vulpecula) -- 4 Conclusions -- References -- Laboratory Diagnosis of Buruli Ulcer: Challenges and Future Perspectives -- 1 Introduction -- 2 Currently Available Laboratory Diagnostic Tests -- 2.1 Specimen Collection and Reference Standards -- 2.2 IS2404 PCR: The Current Gold Standard -- 2.3 Detection of AFBs by Microscopy: A Test for the Primary Healthcare Level with Limited Sensitivity -- 2.4 Considerations on the Accuracy of IS2404 qPCR and AFB Detection by Microscopy: Direct Comparison of the Two Techniques -- 2.5 Histopathology and Cultivation of M. ulcerans: Research Tools Rather than Diagnostic Tests -- 2.6 From Theory into Practice: Diagnosis of BU in Resource-Constrained Endemic Countries. 3 Development of BU Diagnostics for District Hospital or Primary Healthcare Facility Level -- 3.1 LAMP: An Alternative for the Detection of M. ulcerans DNA -- 3.2 Detection of Mycolactone by f-TLC: Struggling with the Complexity of Lipid Extracts -- 3.3 Serological Tests: Only Suitable for Seroepidemiological Studies -- 3.4 Detection of Mycolactone and M. ulcerans Proteins by Antigen Detection Assays: Prospects for the Development of an RDT -- 4 Discussion -- 5 Outlook -- References -- Antimicrobial Treatment of Mycobacterium ulcerans Infection -- 1 Historical Aspects -- 2 Antimicrobial Susceptibility of M. ulcerans -- 2.1 Ansamycins/Rifamycins -- 2.2 Aminoglycosides: Streptomycin -- 2.3 Amikacin -- 2.4 Macrolides: Clarithromycin -- 2.5 Azithromycin -- 2.6 Fluoroquinolones -- 2.7 Clofazimine -- 2.8 Dapsone -- 2.9 Doxycycline -- 2.10 Oxazolidinones -- 2.11 Avermectins -- 2.12 Trimethoprim and Epiroprim -- 3 Experimental Drugs -- 4 Clinical Studies -- 4.1 Secondary Infection -- 4.2 HIV Co-infection -- 5 Conclusions -- Areas of Uncertainty -- and Future Directions -- References -- Thermotherapy of Buruli Ulcer -- References -- Secondary Infection of Buruli Ulcer Lesions -- 1 Background -- 2 Bacterial Species Associated with Secondary Infections -- 2.1 Species Diversity -- 3 Bacterial Burden -- 4 Diagnosing Secondary Infection in BU -- 5 Drug Susceptibility Patterns of Bacterial Isolates from BU Lesions -- 6 Molecular Epidemiology -- 6.1 Sources of Infection -- 7 Predisposing Socio-Economic Factors -- 8 Prevention of Secondary Infection -- 9 Wound Care -- References -- Management of BU-HIV Co-infection -- 1 Epidemiology -- 2 Clinical Effects of BU-HIV Co-Infection -- 3 Diagnosis -- 4 Management of BU-HIV Co-Infection -- 4.1 BU Treatment -- 4.2 HIV Treatment -- 4.3 HIV and BU Treatment Interactions. 4.4 Children -- 4.5 Tuberculosis -- 4.6 Service Provision -- References -- Social Science Contributions to BU Focused Health Service Research in West-Africa -- 1 Introduction -- 2 Part One -- 2.1 Predisposing Factors: Cultural Perceptions of BU Causality, Social Stigma, and Preference for Traditional Healing -- 2.1.1 Cultural Perceptions of BU Causality -- Benin -- Cameroon -- Ghana -- 2.1.2 Stigma and Social Risk -- 2.1.3 Traditional Healers -- Enabling Factors -- 2.2 Service Level Factors Affecting Health Care Seeking and Treatment Adherence -- 3 Part Two: Social Science Inspired Interventions -- 3.1 Outreach Education -- 3.2 Introducing Decentralized BU Care in Ouinhi, Benin -- 3.3 Establishing a BU Community of Practice: Cameroon -- 3.4 Yaws Cases Identified as a Result of BU Outreach in Cameroon: A Case for Integrated Skin Neglected Tropical Disease (NTD) Programs -- 3.5 BU Children's Support Group Ghana -- 3.6 Mhealth as a Tool in Monitoring BU Healing in Ghana -- 3.7 Transforming a BU Hospital into a Therapeutic Community for Inpatients -- 4 Conclusion -- References -- Transdisciplinary Research and Action to Stop Buruli Ulcer: A case Study from Philanthropy -- 1 Introduction -- 2 The Beginnings: Six Reasons Why -- 2.1 Reason #1: Lack of Funding Incentives -- 2.2 Reason #2: A Disease of Social Justice -- 2.3 Reason #3: A Disease with Devastating Consequences -- 2.4 Reason #4: The Pioneer Effect -- 2.5 Reason #5: Existing Critical Mass of Researchers and Implementing Agencies -- 2.6 Reason #6: Scalability and Uptake -- 2.7 Stop Buruli Initiative -- 3 The Model: Transdisciplinary Research and Implementation -- 4 Key Elements for Advancing Transdisciplinarity -- 4.1 Transdisciplinarity Does Not 'Just Happen' -- 4.2 Governance Model -- 5 Results -- 5.1 Diagnosis -- 5.2 Treatment -- 5.3 Transmission. 5.4 Socio-Cultural Aspects. |
author_facet |
Pluschke, Gerd. Röltgen, Katharina. |
author_variant |
g p gp |
author2 |
Röltgen, Katharina. |
author2_variant |
k r kr |
author2_role |
TeilnehmendeR |
author_sort |
Pluschke, Gerd. |
title |
Buruli Ulcer : Mycobacterium Ulcerans Disease. |
title_sub |
Mycobacterium Ulcerans Disease. |
title_full |
Buruli Ulcer : Mycobacterium Ulcerans Disease. |
title_fullStr |
Buruli Ulcer : Mycobacterium Ulcerans Disease. |
title_full_unstemmed |
Buruli Ulcer : Mycobacterium Ulcerans Disease. |
title_auth |
Buruli Ulcer : Mycobacterium Ulcerans Disease. |
title_new |
Buruli Ulcer : |
title_sort |
buruli ulcer : mycobacterium ulcerans disease. |
publisher |
Springer International Publishing AG, |
publishDate |
2019 |
physical |
1 online resource (290 pages) |
edition |
1st ed. |
contents |
Intro -- Preface -- Contents -- Buruli Ulcer: History and Disease Burden -- Buruli Ulcer in Africa -- 1 Introduction -- 2 Management of BU in Africa -- 2.1 Structure of Health Systems in Africa and Implications for the Management of BU -- 2.2 Diagnosis and Treatment of BU -- 3 Geographical Distribution of BU: Reporting of Cases Versus Actual Situation in Africa -- 4 Distribution of BU Among Affected Populations in Africa -- 5 The Etiology of BU in Africa -- 6 Future Perspectives -- References -- Buruli Ulcer in Australia -- 1 Bairnsdale Ulcer and the Discovery of Mycobacterium ulcerans -- 2 Buruli Ulcer in Queensland -- 3 Buruli Ulcer in Victoria -- 4 Buruli Ulcer in Animals in Victoria -- 5 Recent Epidemiology of Buruli Ulcer in Victoria -- 6 Clinical Management of Buruli Ulcer in Australia -- 7 Buruli Ulcer: The Australian Paradox -- References -- Mycobacterium ulcerans Infection in French Guiana -- Current State of Knowledge -- 1 Introduction -- 2 Links Between the Human Host and the Bacteria -- 2.1 Risk Factors of BU in French Guiana -- 2.2 Epidemiology and Clinical Aspects of BU in French Guiana -- 2.3 A Link Between Rainfall and BU Cases -- 2.4 Genetic Diversity of M. ulcerans Among Local BU Cases -- 3 Environment and the Bacteria -- 3.1 First Detection of Mycobacterium ulcerans DNA in Environmental Samples from French Guiana -- 3.2 Biodiversity Drivers of M. ulcerans Distribution Across Freshwater Habitats -- 4 Conclusion -- References -- Buruli Ulcer in Japan -- 1 Epidemiology and Bacteriological and Genomic Features of M. ulcerans subsp. shinshuense -- 1.1 Epidemiology -- 1.2 Genome -- 1.3 Biochemical Properties -- 2 Clinical Features and Treatment of BU in Japan -- 2.1 Antimicrobial Treatment -- 2.2 Alternative Treatments of BU -- 2.3 Other Suggested Therapies. 3 M. ulcerans subsp. shinshuense in the Environment of Japan -- 3.1 Detection of Environmental M. ulcerans subsp. shinshuense in Japan -- 3.2 Seasonal Variation of BU in Japan -- 3.3 PCR Detection of M. ulcerans subsp. shinshuense DNA in the Environment -- 4 BU in Asia and Future Perspectives -- 4.1 BU in China -- 4.2 Toward Detection of BU in Other Asian Countries -- References -- Population Genomics and Molecular Epidemiology of Mycobacterium ulcerans -- 1 First Insights from the Complete Genome of Mycobacterium ulcerans -- 2 An Aquatic Origin and Two Bottlenecks for a Recently Emerged, and Globally Distributed Pathogen -- 3 New Understandings from Genomics on the Spread of M. ulcerans Across Africa -- 4 Genomic Approaches to Micro-Molecular Epidemiological Investigations of BU -- 5 Distinguishing Relapse from Reinfection and Familial Studies -- 6 Summary and Future Perspectives -- References -- Mycolactone: More than Just a Cytotoxin -- 1 Mycolactone and BU Disease -- 1.1 Pharmacodistribution -- 1.2 Mycolactone Contribution to BU Disease Manifestations -- 1.2.1 Pathogenesis and Histopathology of BU Lesions -- 1.2.2 Local Analgesia -- 1.2.3 Local and Systemic Immunomodulation -- 2 Molecular Targets and Mechanisms of Action -- 2.1 Sec61 Blockade -- 2.2 AT2R Stimulation -- 2.3 N-WASP Activation -- 3 Conclusions -- References -- The Immunology of Buruli Ulcer -- 1 Buruli Ulcer: The First Histological Observations of a Necrotic Track -- 2 Host Attempts to Control Mycobacterium ulcerans Infection -- 2.1 Local Immune Response -- 2.2 Regional and Systemic Responses -- 3 Diagnostics Research Make it Evident: The Triggering of Cellular and Humoral Arms -- 4 Antibiotic Treatment in the Aid of the Host Immune Response -- 5 Epidemiological Clues and the Search for Novel Resistance and Susceptibility Markers. 6 (Un)successful Preventive Approaches -- 7 Novel Models for Investigation and Future Perspectives -- 8 Conclusions -- References -- Buruli Ulcer in Animals and Experimental Infection Models -- 1 Naturally Infected Animals -- 2 The Mouse (Mus musculus) Model -- 2.1 History of the BU Mouse Model -- 2.2 Experimental Infection of the Mouse -- 2.2.1 Infection Sites -- 2.2.2 Mouse Strains -- 2.2.3 Mycobacterial Strains Used for Experimental Infection -- 2.2.4 Dose and Preparation of the Bacterial Inocula -- 2.2.5 Infection Outcomes and What to Measure -- 2.3 Research Applications for the Mouse Model -- 2.3.1 Antimicrobial Compound Testing -- 2.3.2 Vaccine Development -- 2.3.3 Study of the Pathogenesis of Buruli Ulcer and the Immune Response to the Disease -- 3 Other Animal Models -- 3.1 Guinea Pig (Cavia porcellus) -- 3.2 Pig (Sus scrofa) -- 3.3 Grasscutter (Thryonomys swinderianus) -- 3.4 Anole Lizard (Anolis carolinensis) -- 3.5 Nine-Banded Armadillo (Dasypus novemcinctus) -- 3.6 Cynomologus Monkey (Maca fascicularis) -- 3.7 African Rat (Mastomys natalensis) -- 3.8 Common Brushtail Possum (Trichosurus vulpecula) -- 4 Conclusions -- References -- Laboratory Diagnosis of Buruli Ulcer: Challenges and Future Perspectives -- 1 Introduction -- 2 Currently Available Laboratory Diagnostic Tests -- 2.1 Specimen Collection and Reference Standards -- 2.2 IS2404 PCR: The Current Gold Standard -- 2.3 Detection of AFBs by Microscopy: A Test for the Primary Healthcare Level with Limited Sensitivity -- 2.4 Considerations on the Accuracy of IS2404 qPCR and AFB Detection by Microscopy: Direct Comparison of the Two Techniques -- 2.5 Histopathology and Cultivation of M. ulcerans: Research Tools Rather than Diagnostic Tests -- 2.6 From Theory into Practice: Diagnosis of BU in Resource-Constrained Endemic Countries. 3 Development of BU Diagnostics for District Hospital or Primary Healthcare Facility Level -- 3.1 LAMP: An Alternative for the Detection of M. ulcerans DNA -- 3.2 Detection of Mycolactone by f-TLC: Struggling with the Complexity of Lipid Extracts -- 3.3 Serological Tests: Only Suitable for Seroepidemiological Studies -- 3.4 Detection of Mycolactone and M. ulcerans Proteins by Antigen Detection Assays: Prospects for the Development of an RDT -- 4 Discussion -- 5 Outlook -- References -- Antimicrobial Treatment of Mycobacterium ulcerans Infection -- 1 Historical Aspects -- 2 Antimicrobial Susceptibility of M. ulcerans -- 2.1 Ansamycins/Rifamycins -- 2.2 Aminoglycosides: Streptomycin -- 2.3 Amikacin -- 2.4 Macrolides: Clarithromycin -- 2.5 Azithromycin -- 2.6 Fluoroquinolones -- 2.7 Clofazimine -- 2.8 Dapsone -- 2.9 Doxycycline -- 2.10 Oxazolidinones -- 2.11 Avermectins -- 2.12 Trimethoprim and Epiroprim -- 3 Experimental Drugs -- 4 Clinical Studies -- 4.1 Secondary Infection -- 4.2 HIV Co-infection -- 5 Conclusions -- Areas of Uncertainty -- and Future Directions -- References -- Thermotherapy of Buruli Ulcer -- References -- Secondary Infection of Buruli Ulcer Lesions -- 1 Background -- 2 Bacterial Species Associated with Secondary Infections -- 2.1 Species Diversity -- 3 Bacterial Burden -- 4 Diagnosing Secondary Infection in BU -- 5 Drug Susceptibility Patterns of Bacterial Isolates from BU Lesions -- 6 Molecular Epidemiology -- 6.1 Sources of Infection -- 7 Predisposing Socio-Economic Factors -- 8 Prevention of Secondary Infection -- 9 Wound Care -- References -- Management of BU-HIV Co-infection -- 1 Epidemiology -- 2 Clinical Effects of BU-HIV Co-Infection -- 3 Diagnosis -- 4 Management of BU-HIV Co-Infection -- 4.1 BU Treatment -- 4.2 HIV Treatment -- 4.3 HIV and BU Treatment Interactions. 4.4 Children -- 4.5 Tuberculosis -- 4.6 Service Provision -- References -- Social Science Contributions to BU Focused Health Service Research in West-Africa -- 1 Introduction -- 2 Part One -- 2.1 Predisposing Factors: Cultural Perceptions of BU Causality, Social Stigma, and Preference for Traditional Healing -- 2.1.1 Cultural Perceptions of BU Causality -- Benin -- Cameroon -- Ghana -- 2.1.2 Stigma and Social Risk -- 2.1.3 Traditional Healers -- Enabling Factors -- 2.2 Service Level Factors Affecting Health Care Seeking and Treatment Adherence -- 3 Part Two: Social Science Inspired Interventions -- 3.1 Outreach Education -- 3.2 Introducing Decentralized BU Care in Ouinhi, Benin -- 3.3 Establishing a BU Community of Practice: Cameroon -- 3.4 Yaws Cases Identified as a Result of BU Outreach in Cameroon: A Case for Integrated Skin Neglected Tropical Disease (NTD) Programs -- 3.5 BU Children's Support Group Ghana -- 3.6 Mhealth as a Tool in Monitoring BU Healing in Ghana -- 3.7 Transforming a BU Hospital into a Therapeutic Community for Inpatients -- 4 Conclusion -- References -- Transdisciplinary Research and Action to Stop Buruli Ulcer: A case Study from Philanthropy -- 1 Introduction -- 2 The Beginnings: Six Reasons Why -- 2.1 Reason #1: Lack of Funding Incentives -- 2.2 Reason #2: A Disease of Social Justice -- 2.3 Reason #3: A Disease with Devastating Consequences -- 2.4 Reason #4: The Pioneer Effect -- 2.5 Reason #5: Existing Critical Mass of Researchers and Implementing Agencies -- 2.6 Reason #6: Scalability and Uptake -- 2.7 Stop Buruli Initiative -- 3 The Model: Transdisciplinary Research and Implementation -- 4 Key Elements for Advancing Transdisciplinarity -- 4.1 Transdisciplinarity Does Not 'Just Happen' -- 4.2 Governance Model -- 5 Results -- 5.1 Diagnosis -- 5.2 Treatment -- 5.3 Transmission. 5.4 Socio-Cultural Aspects. |
isbn |
9783030111144 9783030111137 |
callnumber-first |
Q - Science |
callnumber-subject |
QR - Microbiology |
callnumber-label |
QR46 |
callnumber-sort |
QR 246 |
genre |
Electronic books. |
genre_facet |
Electronic books. |
url |
https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=5771208 |
illustrated |
Not Illustrated |
oclc_num |
1099692389 |
work_keys_str_mv |
AT pluschkegerd buruliulcermycobacteriumulceransdisease AT roltgenkatharina buruliulcermycobacteriumulceransdisease |
status_str |
n |
ids_txt_mv |
(MiAaPQ)5005771208 (Au-PeEL)EBL5771208 (OCoLC)1099692389 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Buruli Ulcer : Mycobacterium Ulcerans Disease. |
author2_original_writing_str_mv |
noLinkedField |
marc_error |
Info : MARC8 translation shorter than ISO-8859-1, choosing MARC8. --- [ 856 : z ] |
_version_ |
1792331056051912704 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>12032nam a22004453i 4500</leader><controlfield tag="001">5005771208</controlfield><controlfield tag="003">MiAaPQ</controlfield><controlfield tag="005">20240229073832.0</controlfield><controlfield tag="006">m o d | </controlfield><controlfield tag="007">cr cnu||||||||</controlfield><controlfield tag="008">240229s2019 xx o ||||0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783030111144</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9783030111137</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(MiAaPQ)5005771208</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(Au-PeEL)EBL5771208</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1099692389</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">MiAaPQ</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">MiAaPQ</subfield><subfield code="d">MiAaPQ</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">QR46</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Pluschke, Gerd.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Buruli Ulcer :</subfield><subfield code="b">Mycobacterium Ulcerans Disease.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cham :</subfield><subfield code="b">Springer International Publishing AG,</subfield><subfield code="c">2019.</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2019.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (290 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Intro -- Preface -- Contents -- Buruli Ulcer: History and Disease Burden -- Buruli Ulcer in Africa -- 1 Introduction -- 2 Management of BU in Africa -- 2.1 Structure of Health Systems in Africa and Implications for the Management of BU -- 2.2 Diagnosis and Treatment of BU -- 3 Geographical Distribution of BU: Reporting of Cases Versus Actual Situation in Africa -- 4 Distribution of BU Among Affected Populations in Africa -- 5 The Etiology of BU in Africa -- 6 Future Perspectives -- References -- Buruli Ulcer in Australia -- 1 Bairnsdale Ulcer and the Discovery of Mycobacterium ulcerans -- 2 Buruli Ulcer in Queensland -- 3 Buruli Ulcer in Victoria -- 4 Buruli Ulcer in Animals in Victoria -- 5 Recent Epidemiology of Buruli Ulcer in Victoria -- 6 Clinical Management of Buruli Ulcer in Australia -- 7 Buruli Ulcer: The Australian Paradox -- References -- Mycobacterium ulcerans Infection in French Guiana -- Current State of Knowledge -- 1 Introduction -- 2 Links Between the Human Host and the Bacteria -- 2.1 Risk Factors of BU in French Guiana -- 2.2 Epidemiology and Clinical Aspects of BU in French Guiana -- 2.3 A Link Between Rainfall and BU Cases -- 2.4 Genetic Diversity of M. ulcerans Among Local BU Cases -- 3 Environment and the Bacteria -- 3.1 First Detection of Mycobacterium ulcerans DNA in Environmental Samples from French Guiana -- 3.2 Biodiversity Drivers of M. ulcerans Distribution Across Freshwater Habitats -- 4 Conclusion -- References -- Buruli Ulcer in Japan -- 1 Epidemiology and Bacteriological and Genomic Features of M. ulcerans subsp. shinshuense -- 1.1 Epidemiology -- 1.2 Genome -- 1.3 Biochemical Properties -- 2 Clinical Features and Treatment of BU in Japan -- 2.1 Antimicrobial Treatment -- 2.2 Alternative Treatments of BU -- 2.3 Other Suggested Therapies.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3 M. ulcerans subsp. shinshuense in the Environment of Japan -- 3.1 Detection of Environmental M. ulcerans subsp. shinshuense in Japan -- 3.2 Seasonal Variation of BU in Japan -- 3.3 PCR Detection of M. ulcerans subsp. shinshuense DNA in the Environment -- 4 BU in Asia and Future Perspectives -- 4.1 BU in China -- 4.2 Toward Detection of BU in Other Asian Countries -- References -- Population Genomics and Molecular Epidemiology of Mycobacterium ulcerans -- 1 First Insights from the Complete Genome of Mycobacterium ulcerans -- 2 An Aquatic Origin and Two Bottlenecks for a Recently Emerged, and Globally Distributed Pathogen -- 3 New Understandings from Genomics on the Spread of M. ulcerans Across Africa -- 4 Genomic Approaches to Micro-Molecular Epidemiological Investigations of BU -- 5 Distinguishing Relapse from Reinfection and Familial Studies -- 6 Summary and Future Perspectives -- References -- Mycolactone: More than Just a Cytotoxin -- 1 Mycolactone and BU Disease -- 1.1 Pharmacodistribution -- 1.2 Mycolactone Contribution to BU Disease Manifestations -- 1.2.1 Pathogenesis and Histopathology of BU Lesions -- 1.2.2 Local Analgesia -- 1.2.3 Local and Systemic Immunomodulation -- 2 Molecular Targets and Mechanisms of Action -- 2.1 Sec61 Blockade -- 2.2 AT2R Stimulation -- 2.3 N-WASP Activation -- 3 Conclusions -- References -- The Immunology of Buruli Ulcer -- 1 Buruli Ulcer: The First Histological Observations of a Necrotic Track -- 2 Host Attempts to Control Mycobacterium ulcerans Infection -- 2.1 Local Immune Response -- 2.2 Regional and Systemic Responses -- 3 Diagnostics Research Make it Evident: The Triggering of Cellular and Humoral Arms -- 4 Antibiotic Treatment in the Aid of the Host Immune Response -- 5 Epidemiological Clues and the Search for Novel Resistance and Susceptibility Markers.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">6 (Un)successful Preventive Approaches -- 7 Novel Models for Investigation and Future Perspectives -- 8 Conclusions -- References -- Buruli Ulcer in Animals and Experimental Infection Models -- 1 Naturally Infected Animals -- 2 The Mouse (Mus musculus) Model -- 2.1 History of the BU Mouse Model -- 2.2 Experimental Infection of the Mouse -- 2.2.1 Infection Sites -- 2.2.2 Mouse Strains -- 2.2.3 Mycobacterial Strains Used for Experimental Infection -- 2.2.4 Dose and Preparation of the Bacterial Inocula -- 2.2.5 Infection Outcomes and What to Measure -- 2.3 Research Applications for the Mouse Model -- 2.3.1 Antimicrobial Compound Testing -- 2.3.2 Vaccine Development -- 2.3.3 Study of the Pathogenesis of Buruli Ulcer and the Immune Response to the Disease -- 3 Other Animal Models -- 3.1 Guinea Pig (Cavia porcellus) -- 3.2 Pig (Sus scrofa) -- 3.3 Grasscutter (Thryonomys swinderianus) -- 3.4 Anole Lizard (Anolis carolinensis) -- 3.5 Nine-Banded Armadillo (Dasypus novemcinctus) -- 3.6 Cynomologus Monkey (Maca fascicularis) -- 3.7 African Rat (Mastomys natalensis) -- 3.8 Common Brushtail Possum (Trichosurus vulpecula) -- 4 Conclusions -- References -- Laboratory Diagnosis of Buruli Ulcer: Challenges and Future Perspectives -- 1 Introduction -- 2 Currently Available Laboratory Diagnostic Tests -- 2.1 Specimen Collection and Reference Standards -- 2.2 IS2404 PCR: The Current Gold Standard -- 2.3 Detection of AFBs by Microscopy: A Test for the Primary Healthcare Level with Limited Sensitivity -- 2.4 Considerations on the Accuracy of IS2404 qPCR and AFB Detection by Microscopy: Direct Comparison of the Two Techniques -- 2.5 Histopathology and Cultivation of M. ulcerans: Research Tools Rather than Diagnostic Tests -- 2.6 From Theory into Practice: Diagnosis of BU in Resource-Constrained Endemic Countries.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3 Development of BU Diagnostics for District Hospital or Primary Healthcare Facility Level -- 3.1 LAMP: An Alternative for the Detection of M. ulcerans DNA -- 3.2 Detection of Mycolactone by f-TLC: Struggling with the Complexity of Lipid Extracts -- 3.3 Serological Tests: Only Suitable for Seroepidemiological Studies -- 3.4 Detection of Mycolactone and M. ulcerans Proteins by Antigen Detection Assays: Prospects for the Development of an RDT -- 4 Discussion -- 5 Outlook -- References -- Antimicrobial Treatment of Mycobacterium ulcerans Infection -- 1 Historical Aspects -- 2 Antimicrobial Susceptibility of M. ulcerans -- 2.1 Ansamycins/Rifamycins -- 2.2 Aminoglycosides: Streptomycin -- 2.3 Amikacin -- 2.4 Macrolides: Clarithromycin -- 2.5 Azithromycin -- 2.6 Fluoroquinolones -- 2.7 Clofazimine -- 2.8 Dapsone -- 2.9 Doxycycline -- 2.10 Oxazolidinones -- 2.11 Avermectins -- 2.12 Trimethoprim and Epiroprim -- 3 Experimental Drugs -- 4 Clinical Studies -- 4.1 Secondary Infection -- 4.2 HIV Co-infection -- 5 Conclusions -- Areas of Uncertainty -- and Future Directions -- References -- Thermotherapy of Buruli Ulcer -- References -- Secondary Infection of Buruli Ulcer Lesions -- 1 Background -- 2 Bacterial Species Associated with Secondary Infections -- 2.1 Species Diversity -- 3 Bacterial Burden -- 4 Diagnosing Secondary Infection in BU -- 5 Drug Susceptibility Patterns of Bacterial Isolates from BU Lesions -- 6 Molecular Epidemiology -- 6.1 Sources of Infection -- 7 Predisposing Socio-Economic Factors -- 8 Prevention of Secondary Infection -- 9 Wound Care -- References -- Management of BU-HIV Co-infection -- 1 Epidemiology -- 2 Clinical Effects of BU-HIV Co-Infection -- 3 Diagnosis -- 4 Management of BU-HIV Co-Infection -- 4.1 BU Treatment -- 4.2 HIV Treatment -- 4.3 HIV and BU Treatment Interactions.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">4.4 Children -- 4.5 Tuberculosis -- 4.6 Service Provision -- References -- Social Science Contributions to BU Focused Health Service Research in West-Africa -- 1 Introduction -- 2 Part One -- 2.1 Predisposing Factors: Cultural Perceptions of BU Causality, Social Stigma, and Preference for Traditional Healing -- 2.1.1 Cultural Perceptions of BU Causality -- Benin -- Cameroon -- Ghana -- 2.1.2 Stigma and Social Risk -- 2.1.3 Traditional Healers -- Enabling Factors -- 2.2 Service Level Factors Affecting Health Care Seeking and Treatment Adherence -- 3 Part Two: Social Science Inspired Interventions -- 3.1 Outreach Education -- 3.2 Introducing Decentralized BU Care in Ouinhi, Benin -- 3.3 Establishing a BU Community of Practice: Cameroon -- 3.4 Yaws Cases Identified as a Result of BU Outreach in Cameroon: A Case for Integrated Skin Neglected Tropical Disease (NTD) Programs -- 3.5 BU Children's Support Group Ghana -- 3.6 Mhealth as a Tool in Monitoring BU Healing in Ghana -- 3.7 Transforming a BU Hospital into a Therapeutic Community for Inpatients -- 4 Conclusion -- References -- Transdisciplinary Research and Action to Stop Buruli Ulcer: A case Study from Philanthropy -- 1 Introduction -- 2 The Beginnings: Six Reasons Why -- 2.1 Reason #1: Lack of Funding Incentives -- 2.2 Reason #2: A Disease of Social Justice -- 2.3 Reason #3: A Disease with Devastating Consequences -- 2.4 Reason #4: The Pioneer Effect -- 2.5 Reason #5: Existing Critical Mass of Researchers and Implementing Agencies -- 2.6 Reason #6: Scalability and Uptake -- 2.7 Stop Buruli Initiative -- 3 The Model: Transdisciplinary Research and Implementation -- 4 Key Elements for Advancing Transdisciplinarity -- 4.1 Transdisciplinarity Does Not 'Just Happen' -- 4.2 Governance Model -- 5 Results -- 5.1 Diagnosis -- 5.2 Treatment -- 5.3 Transmission.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">5.4 Socio-Cultural Aspects.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="590" ind1=" " ind2=" "><subfield code="a">Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. </subfield></datafield><datafield tag="655" ind1=" " ind2="4"><subfield code="a">Electronic books.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Röltgen, Katharina.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Pluschke, Gerd</subfield><subfield code="t">Buruli Ulcer</subfield><subfield code="d">Cham : Springer International Publishing AG,c2019</subfield><subfield code="z">9783030111137</subfield></datafield><datafield tag="797" ind1="2" ind2=" "><subfield code="a">ProQuest (Firm)</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=5771208</subfield><subfield code="z">Click to View</subfield></datafield></record></collection> |